SCHEMBL13602467

SCHEMBL13602467

CC(=O)c1ccc(NC(=O)C(F)(F)F)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.54
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
NR1H4 Q96RI1 2/20 0.49
EPHX2 P34913 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 2/20 0.48
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
KMT2A Q03164 1/20 0.46
NPY5R Q15761 1/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
RORC P51449 1/20 0.44
KDR P35968 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13690062 0.88 L3MBTL1 (0.51) L3MBTL1CYP1A2CYP2C9CYP2C19NR1H4
SCHEMBL8278647 0.88 L3MBTL1 (0.58) L3MBTL1CYP1A2CYP2C9CYP2C19NR1H4
SCHEMBL17185584 0.85 CYP1A2 (0.56) L3MBTL1CYP1A2CYP2C9CYP2C19NR1H4
SCHEMBL13602364 0.82 RORC (0.59) EPHX2SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4403329 0.82 EPHX1 (0.63) L3MBTL1CYP1A2CYP2C9CYP2C19EPHX2
SCHEMBL7897266 0.81 L3MBTL1 (0.54) L3MBTL1CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL16621003 0.81 SMN1; SMN2 (0.60) L3MBTL1CYP1A2CYP2C9CYP2C19NR1H4
SCHEMBL18152989 0.80 NPC1 (0.50) EPHX2SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4082732 0.79 L3MBTL1 (0.55) L3MBTL1CYP1A2CYP2C9CYP2C19EPHX2
SCHEMBL13690000 0.79 L3MBTL1 (0.55) L3MBTL1CYP1A2CYP2C9CYP2C19NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325962-A1 TYROSINE DERIVATIVE GENENTECH, INC. (US) 2009-12-31 US disclosed
US-20090325962-A1 TYROSINE DERIVATIVE GENENTECH, INC. (US) 2009-12-31 US disclosed
US-7595399-B2 Tyrosine derivatives GENENTECH, INC. (US) 2009-09-29 US disclosed
US-7595399-B2 Tyrosine derivatives GENENTECH, INC. (US) 2009-09-29 US disclosed
US-20080075719-A1 Method for Augmenting B Cell Depletion GENENTECH, INC. (US) 2008-03-27 US disclosed
US-20080075719-A1 Method for Augmenting B Cell Depletion GENENTECH, INC. (US) 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325962-A1 TYROSINE DERIVATIVE VCAM1, ICAM1, ITGB4 L3MBTL1 1574/4885CYP1A2 2883/4885CYP2C9 1971/4885
US-20080075719-A1 Method for Augmenting B Cell Depletion CD22, ITGAM, FCGR3B L3MBTL1 769/4885CYP1A2 3933/4885CYP2C9 4672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.